Solid Biosciences Inc. filings document regulatory disclosures for a Nasdaq-listed precision genetic medicine company developing gene therapies for rare neuromuscular and cardiac diseases. Its SEC records include Form 8-K reports on operating and financial results, Regulation FD presentations, clinical updates for SGT-003 and the INSPIRE DUCHENNE trial, material agreements, and capital-structure matters.
Proxy filings describe annual stockholder meeting proposals, board classification matters, advisory votes, executive compensation, and equity awards. The filing record also identifies the company’s common stock as listed on The Nasdaq Global Select Market under the SLDB symbol.
Solid Biosciences reported insider sale activity by Kevin Tan: reported sales include 5,704 shares for $30,060.08 on 01/13/2026, 26,837 shares for $172,747.09 on 02/02/2026, and 14,783 shares for $95,226.63 on 02/04/2026. The filing also records 5,404 shares associated with settlement of vested restricted stock units on 02/18/2026.
Solid Biosciences Inc. Chief Financial Officer and Treasurer Kevin Tan reported RSU vesting and related share activity. On February 13, 2026, 10,625 restricted stock units converted into 10,625 shares of common stock at no cost, leaving 21,250 RSUs outstanding and 104,826 common shares held directly.
On February 18, 2026, Tan sold 5,404 common shares at a weighted average price of $5.8233 per share to cover withholding taxes after the RSU vesting, under a durable automatic sales instruction adopted on August 15, 2024. The sale was not a discretionary trade, and he now directly holds 99,422 common shares.
Solid Biosciences Inc. received a Schedule 13G reporting that investment adviser Vestal Point Capital, LP and its Chief Investment Officer Ryan Wilder beneficially own 5,815,000 shares of common stock. This represents 7.5% of the outstanding shares, based on 77,910,239 shares outstanding as of October 29, 2025.
The shares are held through a fund and managed account advised by Vestal Point Capital. The filing states the holdings were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Solid Biosciences.
Solid Biosciences Inc. received an updated ownership disclosure from Adage Capital affiliates. Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 1,400,000 shares of Solid Biosciences common stock, representing 1.80% of the outstanding shares as of October 29, 2025.
The shares are held through Adage Capital Partners, L.P., with shared voting and dispositive power and no sole voting or dispositive power reported. The filing is on a passive Schedule 13G/A basis, and the reporting group confirms the position is held in the ordinary course of business and not to change or influence control of the company.
Solid Biosciences Chief Operating Officer sells shares to cover taxes. On February 4, 2026, COO David T. Howton sold 18,894 shares of Solid Biosciences common stock at a weighted average price of $6.4419 per share.
The filing explains this was an automatic sale to cover withholding taxes after restricted stock units vested, under a pre-established durable automatic sale instruction. It states the transaction was not a discretionary trade. After this sale, Howton directly owned 97,859 shares of common stock.
Solid Biosciences Inc. President and CEO Alexander Cumbo reported an automatic sale of common stock tied to tax withholding. On February 4, 2026, he sold 48,913 shares of Solid Biosciences common stock at a weighted average price of $6.4419 per share.
The filing explains this was a sell-to-cover transaction to satisfy withholding taxes after previously granted restricted stock units vested, executed under a durable automatic sale instruction letter adopted on August 18, 2024. After this activity, Cumbo directly beneficially owned 222,018 common shares.
Solid Biosciences Inc. director Ilan Ganot reported an indirect sale of 7,205 shares of common stock on February 4, 2026 at a weighted average price of $6.4419 per share. The shares were held through his spouse and sold to cover withholding taxes after previously granted restricted stock units vested, under a durable automatic sell-to-cover instruction, so the transaction was not a discretionary trade.
Following this transaction, Ganot is reported as beneficially owning 25,271 shares indirectly through his wife, 99,297 shares directly (including shares held individually and jointly with Annie Ganot), and 19,394 shares indirectly through the Ilan Ganot 2017 Irrevocable Trust.
Solid Biosciences Inc. CFO and Treasurer Kevin Tan reported an automatic sale of 14,783 shares of common stock on February 4, 2026. The shares were sold at a weighted average price of $6.4419 per share, in multiple trades between $6.28 and $6.60.
The sale was made solely to cover withholding taxes after previously granted restricted stock units vested, under a durable automatic sale instruction letter adopted on August 15, 2024, and is not a discretionary trade by Mr. Tan. Following this transaction, he directly holds 94,201 common shares.
Solid Biosciences Inc. Chief Medical Officer Gabriel Brooks reported an automatic sale of 12,616 shares of common stock on February 4, 2026. The shares were sold at a weighted average price of $6.4419 per share to cover withholding taxes upon vesting of previously granted restricted stock units, under a durable automatic sale instruction letter.
After this tax-withholding sale, Dr. Brooks beneficially owns 84,092 shares of Solid Biosciences common stock in direct form. The company’s disclosure notes that the transaction did not represent a discretionary trade by Dr. Brooks, and that the individual sale prices ranged from $6.28 to $6.60 per share.
Solid Biosciences Inc. insider transaction: Chief Regulatory Officer Jessie Hanrahan reported an automatic sale of common stock tied to tax withholding. On February 4, 2026, 12,348 shares of common stock were sold at a weighted average price of $6.4419 per share to cover withholding taxes after restricted stock units vested. The filing notes this was executed under a pre-established durable automatic sale instruction and is not a discretionary trade. After the transaction, Hanrahan beneficially owned 70,327 shares of Solid Biosciences common stock in direct ownership.